IO Biotech Provides Business Update
NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine platform, today provided a business update.
Related news for (IOBT)
- IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025
- MoBot alert highlights: NASDAQ: RUN, NASDAQ: CASI, NYSE: UP, NASDAQ: IOBT, NASDAQ: GANX (08/15/25 02:00 PM)
- Don’t Miss Out: MoBot’s Latest Stock Updates 08/15/25 08:00 AM
- MoBot alert highlights: NASDAQ: ATNF, NASDAQ: IOBT, NASDAQ: TRIB, NASDAQ: XFOR, NYSE: DDD (08/12/25 10:00 AM)
- MoBot alert highlights: NASDAQ: RMBL, NASDAQ: MRVI, NASDAQ: IOBT, NYSE: DDD, NASDAQ: ONDS (08/12/25 09:00 AM)